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Abstract
Tauopathies are prevalent, invariably fatal brain diseases for which no cure is available. 
Tauopathies progressively affect the brain through cell-to-cell transfer of tau protein amyloids, yet 
the spreading mechanisms are unknown. Here we show that the cellular prion protein (PrPC) 
facilitates the uptake of tau aggregates by cultured cells, possibly by acting as an endocytic 
receptor. In mouse neuroblastoma cells, pull-down experiments revealed that tau amyloids bind 
to PrPC; Confocal images of both wild-type and PrPC - knockout N2a cells treated with 
fluorescently labelled synthetic tau fibrils showed that the internalization was reduced in isogenic 
cells devoid of the gene encoding PrPC. Pre-treatment of the same cells with antibodies against 
N-proximal epitopes of PrPC impaired the binding of tau amyloids and decreased their uptake. 
Surprisingly, exposure of chronically prion-infected cells to tau amyloids reduced the 
accumulation of aggregated prion protein; this effect lasted for more than 72 hours after amyloid 
removal. These results point to bidirectional interactions between the two proteins: whilst PrPC 
mediates the entrance of tau fibrils in cells, PrPSc buildup is greatly reduced in their presence, 















AFM: Atomic Force Microscopy
CNS: Central Nervous System
HPSGs: heparan sulfate proteoglycans
mGluR5: metabotropic glutamate receptor 5 
N2a: Neuro-2a cell line 
PK: proteinase K
PrPC : cellular prion protein
PrPSc : scrapie prion protein
RRID: Research Resource Identifier
sCJD: sporadic CJD
SNpc: substantia nigra pars compacta
ThT: Thioflavin T
TEM: Transmission Electron Microscopy
Introduction
Tauopathies are a clinically heterogeneous group of diseases that affect many different anatomic 
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protein within neurons of the central nervous system (CNS). These aggregates have the 
morphology of fibrils and the tinctorial property of amyloid, i.e. they can be stained by Congo red 
and thioflavin  T. 
Several in vitro and in vivo studies showed that, at least to some extent, tau amyloids are able to 
recruit and seed the aggregation of the endogenous protein, therefore initiating the spreading 
from neuron to neuron (Khlistunova et al. 2006; Mirbaha et al. 2015; Holmes et al. 2014; Sanders 
et al. 2014; Falcon et al. 2015; Clavaguera et al. 2009; Clavaguera et al. 2013; Iba et al. 2015; 
Guo & Lee 2011). These findings, together with the observation that tauopathies progress in the 
CNS along predictable, neuroanatomically connected circuits (Braak & Braak 1991), led to the 
hypothesis that they might share some specific features with another group of neurodegenerative 
diseases, prion disorders. Unlike for prions, tau amyloids do not seem to undergo a fully 
infectious cycle, and horizontal propagation of tauopathies has not been demonstrated. Hence, 
tau aggregates are now considered to be “prion-like” proteins, or “prionoids” (Aguzzi 2009), along 
with -synuclein and amyloid-. 
Cell-to-cell transfer of tau aggregates is mediated by several mechanisms (endocytosis, receptor-
mediated endocytosis, macropinocytosis, tunneling nanotubes) (Holmes et al. 2013; Frost et al. 
2009; Wu et al. 2013) that contribute to various extent to the propagation of the amyloids 
between cells. While some of these pathways are exclusive for tau, some others are exploited 
also by other neurodegeneration-related proteins. For example, -synuclein is also thought to be 
transported along tunneling nanotubes (Tardivel et al. 2016). 
Recent evidence proposes that the cellular prion protein (PrPC) might underlie the progression of 
several distinct neurodegenerative disorders (Resenberger et al. 2011), both promoting the 
spreading of the misfolded proteins and mediating their neurotoxic effects. Indeed, the presence 
of PrPC on the cell membrane is essential for the progression of prion disorders, and may be 
involved in the A-associated neurotoxicity in Alzheimer’s disease (AD) (Resenberger et al. 2012; 
Um et al. 2012), although the latter finding remains controversial (Calella et al. 2010). 
In the case of Parkinson’s disease, PrPC may influence its pathogenesis in two ways: by acting as 
a receptor for -synuclein aggregates that facilitates their internalization in healthy cells, and by 
mediating their toxic effects through the activation of a signaling cascade (Aulic et al. 2017; 
Ferreira et al. 2017). Interestingly, both A- and -synuclein-associated detrimental effects of 
PrPC, as well as those of bona fide prion diseases, proceed through the activation of the mGluR5 
receptor and fyn kinase, corroborating the hypothesis of a common mechanism (Um et al. 2012; 
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Interestingly, targeting PrPC with antibodies reduces the impairment of long-term potentiation 
caused by soluble forms of tau, therefore suggesting a role for the prion protein also in the 
progression of tauopathies (Ondrejcak et al. 2018; Ondrejcak et al. 2019). Since tau fibrils are 
mainly intracellular, it is worth investigating if PrPC is involved in the uptake process of the 
aggregates, as it happens in the case of -synuclein. 
In the present study, we report that PrPC expression enhances the entry of tau fibrils into mouse 
neuroblastoma cells. Conversely, blocking PrP with antibodies reduced the number of 
internalized fibrils. These findings suggest that impairing the binding of the fibrils to PrPC might 
not only to ameliorate synaptic dysfunctions, but also impair the spreading of the aggregates to 
neighboring neurons. Most surprisingly, we discovered that tau fibrils interfere with PrPSc 
accumulation in prion-infected cell lines. We show that the addition of tau K18 amyloids to 
cultured cells causes a rapid and drastic decrease in PrPSc . We found that the treatment 
increases the -cleavage of PrPC into the neuroprotective fragments N1 and C1, thus depleting 
the pool of misfolding-prone protein and impeding prion conversion. 
Materials and methods
This study was not pre-registered. No blinding was performed. 
Ethical statement
Institutional ethical was not required for this study.
Production and fibrillization of recombinant tau K18
Expression and purification of recombinant tau K18 fragment were performed as previously 
described (Barghorn et al. 2005). In vitro fibrillization reactions were prepared in a 96-well black 
plate with transparent bottom (BD Falcon) in a final volume of 200 µL per well. Fibrillization 
reaction was composed as follows: tauK18 0.5 mg/mL, heparin 10 µg/mL, DTT 0.1 mM, PBS 1X 
pH 7.4. Due to its toxicity to cultured cells, 10 µM Thioflavin T was added only in 4 wells that were 
used to monitor the aggregation reaction in real-time. Each well contained also a 3-mm glass 
bead (Sigma). The plate was covered with sealing tape (Fisher Scientific) and incubated at 37°C 
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FLUOstar Omega (BMG Labtech) microplate reader. Fluorescence was monitored every 30 
minutes by bottom reading at 444 nm of excitation and 485 nm of emission. For cell culture 
experiments, fibrillization was perfomed as described above but in absence of ThT. The reaction 
was stopped after 15 hours, when fluorescence reached plateau. Newly formed aggregates were 
pelleted by ultracentrifugation (55000 rpm for 1 hour at 4°C), resuspended in an equal volume of 
sterile PBS and stored at -20°C. Before use, aliquots were thawed and sonicated for 5 minutes in 
a sonicator Misonix s3000 at 250 W.
AFM and TEM analysis
AFM analysis was performed in tapping mode. 10 μL of fibril solution was deposited onto a 
freshly cleaved piece of mica and left to adhere for 30 min. Samples were then washed with 
distilled water and blow-dried under a flow of nitrogen. Images were collected at a line scan rate 
of 0.5-2 Hz in ambient conditions. The AFM free oscillation amplitudes ranged from 25 nm to 40 
nm, with characteristic set points ranging from 75% to 90% of these free oscillation amplitudes. 
AFM data were analysed with Gwyddion (gwyddion. net).
For TEM analysis, 10 μL of fibrils solution was dropped onto 200-mesh Formvar-carbon coated 
nickel grids (Electron Microscopy  Sciences) for 20 min and the remaining drop was blotted dry 
using Whatman filter paper. Subsequently, the samples were stained with 25% Uranyl Acetate 
Replacement (UAR, Electron Microscopy  Sciences) for 10 min. The staining solution was 
removed using Whatman filter paper and the grids were air-dried for 5 min before the analyses. 
Amyloid samples were visualized using a FEI Tecnai Spirit Transmission Electron Microscope 
operating at 120 kV and equipped with an Olimpus Megaview G2 camera.
Cell culture
Mouse neuroblastoma cells N2a were kindly provided by Prof. Chiara Zurzolo (Unité de traffic 
membranaire et pathogenèse, Institute Pasteur, Paris, France). N2a Prnp-/- cells were kindly 
provided by professor Gerold Schmitt-Ulms (Tanz Centre for Research in Neurodegenerative 
Diseases, University of Toronto, Toronto, Ontario, Canada), for which they used the CRISPR-
Cas9-Based Knockout system to ablate the expression of PrP protein (Mehrabian et al. 2014). 
ScN2a cells are clones persistently infected with the RML prion strain as described by Prusiner’s 
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minimal essential medium (MEM) + glutamax (Thermo Fisher Scientific Inc.), supplemented with 
10% fetal bovine serum, 1% non-essential aminoacids, and 100 units/ml penicillin and 100 μg/ml 
streptomycin. The cell lines are not listed as commonly misidentified cell lines by the International 
Cell Line Authentication Commettee. The cells were kept in culture for 6 passages maximum. 
TauK18 fibrils treatment in cell lines
TauK18 amyloids were added to the cell culture medium of N2a, N2a Prnp-/- and ScN2a cell lines 
in 10 cm plates, and incubated for a variable amount of time according to the specific 
experimental setting (ranging from 1 day to 6 days). For the evaluation of PrPSc clearance in 
ScN2a cell line, cells were split and maintained for five additional passage in fibrils-free cell 
culture medium. For fluorescence quantification of amyloids internalization, cells were plated in 
24-wells plates on 12 mm coverslips and incubated with Alexa488-labeled fibrils for 24 – 72 
hours. Labelling with Alexa-488 succinimidyl ester (ThermoFisher) was performed according to 
manufacturer’s instructions. Unbound dye was removed by subsequents steps of dyalisis. 
 Pull-down assay
N2a cells were lysed in lysis buffer (0.1% NP40, 50 mM TrisHCl pH 8, 150 mM NaCl) containing 
one tablet of Complete™ ULTRA Tablets, EDTA-free, glass vials Protease Inhibitor Cocktail 
(Roche). Total protein content was quantified using bicinchoninic acid protein (BCA) 
quantification kit (Pierce). For inhibition of the interaction using POM12, N2a cell lysate was 
incubated for 1 hour with POM12 (15 µg/mL) at 37°C. 1 mg of total protein content was diluted in 
lysis buffer to a final volume of 500 µL, then biotinylated tauK18 fibrils were added to a final 
concentration of 2 µM. Samples were left standing on a rotor wheel overnight at 4°C. The day 
after, 30 µL were collected from each sample and stored at -20°C for further analysis (input 
samples). 30 µL of neutravidin bead slurry (NeutrAvidin Agarose Resins, ThermoFisher Scientific) 
were added to each tube, and the samples were incubated on the rotor wheel at 4°C for 4 hours. 
To precipitate the beads, the samples were centrifuged at 4°C for 2 minutes at 2000 rpm, the 
pellet was washed with three subsequent steps of resuspension in lysis buffer and centrifugation, 
and finally resuspended in 20 µL of Laemmli loading buffer. Samples were boiled for 10 minutes 
and centrifuged at 13000 rpm for 1 minutes to detach and pellet the beads, respectively. The 
supernatants were collected and stored at -20°C for further analysis. 
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30000 cells were cultured on each coverslip and treated with different concentrations of 
Alexa488-labeled tau K18 amyloids. Before fixation, cells were washed twice with sterile PBS and 
incubated for 5 minutes with a sterile 1:1 solution of Trypan Blue : PBS. As shown by Karpowicz 
et al.(Karpowicz et al. 2017), Trypan Blue quenches green fluorescence through an energy-
transfer mechanism, but being unable to enter alive cells, only the fluorescence coming from non-
internalized fibrils is quenched. 
Cells were then rinsed three times with sterile PBS and fixed for 10 minutes with 4% 
paraformaldehyde/PBS. After three washing steps, cells were permeabilized for 5 minutes with 
0.2% Triton X-100/PBS, rinsed again with PBS and incubated for 1 hour with HCS Blue Cell 
Mask (ThermoFisher Scientific) diluted 1:1000, a specific dye that labels the whole cell 
cytoplasm. Coverslips were mounted in Fluoromount-GTM (ThermoFisher Scientific) and stored at 
4°C for confocal fluorescence microscopy. Images were acquired using a Nikon confocal 
microscope (Nikon C1). 
Inhibition of tau K18 amyloids internalization using POM monoclonals
Anti-PrPC monoclonal antibodies were kindly provided by Prof. Adriano Aguzzi (Institute of 
Neuropathology, University of Zürich) (Polymenidou et al. 2008). N2a cells plated on coverslips 
were pre-treated with each POM antibody (15 µg/mL) for 1 hour at 37°C, followed by incubation 
with Alexa488-labeled tauK18 fibrils for 24 hours. Coverslips were processed and mounted as 
described above. To check the binding of POM antibodies to membrane PrPC, cells treated with 
POM antibodies for 1 hour were fixed with 4% paraformaldehyde:PBS for 10 minutes, then 
blocked with 2% FBS for 30 minutes and incubated with Alexa594-conjugated goat anti-mouse 
IgG diluted 1:200 for 1 hour.
Uptake quantification
The uptake quantification was performed in blind on a total of four hundred cells in three 
independent experiments. Random fields on each coverslip were captured at 63x magnification 
(digital zoom 3X) using Nikon C1 confocal microscope. Images were acquired as stacks of 30 - 
40 optical sections of 0.27 µm, 526 x 526, and subsequently deconvolved with a 3D 
deconvolution algorithm (in blind) of the NIS Elements software. Deconvolution was applied only 
to the green channel, as it allows a better separation of the green dots representing the fibrils. 
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internalized fibrils were counted using a home-made script which intersects the objects 
recognized in the green channel with the 3D reconstruction of the cellular volume (blue channel). 
To discriminate the signals corresponding to fibrils from the background, we used the volume of a 
single monomer of synuclein as a threshold. Synuclein is very similar to tau K18 in terms of 
molecular weight and unfolded structure. The volume of a monomer in its multiple conformations 
was obtained from Zhang et al. (Zhang et al. 2018)
Membrane immunostaining of PrPC
N2a cells seeded on coverslips were treated for 24 – 72 hours with 2 µM of tau K18 amyloids. 
Surface staining of PrPC was performed as described in Stincardini et al. (Stincardini et al. 2017). 
Cells were incubated with W226 antibody diluted 1:250 in Opti-MEM (Life Technologies) for 15 
minutes at 4°C, followed by washing in PBS and fixation with 4% paraformaldehyde:PBS for 10 
minutes. Coverslips were then washed three times with PBS, incubated with blocking solution 
(2% FBS in PBS) for 30 minutes and incubated with Alexa-594 conjugated goat anti-mouse IgG 
(Invitrogen) diluted 1:200 in blocking solution. Finally, nuclei were counterstained with DAPI 
(1:1000). Coverslips were mounted in Fluoromount-GTM (ThermoFisher Scientific) and stored at 
4°C. Images were acquired with Nikon C1 confocal at 63x magnification, both as 2D-images of 
medial planes and series of 30-40 optical sections ( z-step = 0.27 µm, 526x526).
Quantification of membrane staining
Quantification of membrane staining was performed with Volocity Workstaton (PerkinElmer) on 
2D images. Image segmentation consisted first of nuclei identification by the DAPI signal, and 
selection of the region of interest by the Alexa-594 signal. Mean fluorescence intensity values of 
Alexa594-conjugated anti-PrP antibody were measured for more than 600 objects per coverslip, 
and weighted averages were calculated in order to identify any difference between untreated and 
treated samples. To confirm that 2D quantification is representative of the situation of the whole 
cell membrane, the same 3D analysis was performed on a number of  z-stacks from both 
untreated and treated samples.
Western blotting
Total protein contents of N2a untreated and treated with 2 µM of tau K18 amyloids were 
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proteins were used and additioned with 5X loading buffer in a ratio 1:5. The samples were boiled 
at 100°C for 10 minutes, loaded onto a 12% Tris-Glycine SDS-PAGE gel and transferred onto 
Immobilon P PVDF membranes (Millipore) for 2 hours at 4°C. The membrane was blocked in 5% 
non-fat milk and incubated overnight at 4°C with human anti-PrP antibodies (D18 1:1000, W226 
1:1000, SAF34 1:1000). The membrane was washed three times with TBS buffer additioned with 
0.2% Triton X-100, incubated for 45 minutes at room temperature with goat anti-human IgG 
conjugated with horseradish peroxidase and developed with the enhanced chemiluminescent 
system. After the acquisition, the membrane was incubated for 30 minutes at room temperature 
with anti β-actin (1:10000, Sigma-Aldrich), which is used as a normalizer. Images were acquired 
with Uvitec Alliance (Cambridge) and densitometric analysis was performed using Uviband 
analysis software. Data are expressed as mean ± SD, and the values of the controls are adjusted 
to 100%. For tau fibrils detection, the membrane was probed with anti-4R tau RD4 antibody 
diluted 1:1000. 
Total RNA extraction and RT-PCR analysis
The total RNA extraction was performed using PureLink RNA MiniKit with TRIzol® Reagent  (Life 
Technologies) following the manufacturer’s instruction. Briefly, control cells and cells treated with 
tauK18 fibrils were washed twice with PBS 1X and lysed using the TRIzol® Reagent. Following 
RNA isolation, a DNase I digestion was performed using 1 unit of enzyme per μg RNA for 15 min 
at room temperature, and RNA clean-up was implemented using RNeasy spin columns following 
the instructions. RNA concentration was determined using the NanoDrop system (Thermo 
Scientific). First-strand cDNA was synthesized using 3 μg of total RNA in a 20 μL reverse 
transcription reaction (RT+ samples) mixture following the instructor manual. For each sample a 
non-retrotranscribed sample was carried along as a negative control (RT− sample).
The cDNA was diluted to 10 ng/μL final concentration prior to Real-Time PCR reactions. 1 ng of 
cDNA was added to the reaction mix including 2× iQ™ SYBR® Green Supermix (Bio-Rad 
Laboratories, Inc.), 400 nM of the corresponding forward and reverse primer (Sigma), and 
quantified in technical duplicates on an iQ5 Multicolor Real-Time PCR Detection System (Bio-
Rad Laboratories, Inc.).
After initial denaturation for 3 min at 95°C, 45 cycles were performed at 95°C for 10 sec and 60°C 
for 1 min. Differential gene expression of was normalized to GAPDH expression. RT– controls 
were included in the plates for each primer pair and sample. The relative expression ratio was 
calculated using the ΔΔCT method [299]. Significance was calculated with the unpaired student t-










This article is protected by copyright. All rights reserved
Gene Chromosome Primer sequence Amplicon 
length (bp)
GAPDH 11 F: CCTGCACCACCAACTGCTTA 
R: CTGTCACCTTCACCGTTCC 
74





PNGase F treatment (New England Biolabs) was performed on control and K18-treated ScN2a 
cell lysates. Twenty µg of total proteins were incubated with 1 µL of Glycoprotein Denaturating 
Buffer (10X) and water to reach a total reaction volume of 10 µL, then the mix was heated at 100 
°C for 10 minutes to denature the proteins. The solution was chilled on ice and centrifuged for 10 
seconds, then additioned with 2 µl of GlycoBuffer 2 (10X), 2 µl of 10% NP-40, 6 µl of H2O and 1 
µl of PNGase F. The solution was incubated overnight at 37°C. Deglycosylated proteins were 
then analysed by Western Blot.
Statistical Analysis
All statistical analysis were performed using GraphPad Prism software (version 7.0a) (RRID: 
SCR_002798). Values were expressed as mean ± standard deviation (SD). For the quantification 
of the internalized fibrils, the ROUT test for the identification of outliers was performed. As the 
sample sizes exceeded n=30, according to the Central Limit Theorem, we assumed a gaussian 
distribution of our data, and used the Student’s T test with Welch correction for the comparison of 
the two groups. The same analysis was repeated also using Mann-Whitney non-parametric test. 
Comparisons of multiple groups versus a control group were evaluated with one-way ANOVA 
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Results
The presence of PrPC on the cell membrane facilitates the uptake of tau K18 amyloids. 
To test whether PrPC expression affects in some way the entrance of tau K18 amyloids in cells, 
we compared the number of internalized fibrils in wild-type N2a cells expressing physiological 
levels of the prion protein to that of N2a cells ablated for PrPC (N2a Prnp-/-, obtained using the 
Crispr-Cas9 Based Knockout system (Kessels et al. 2010)). Synthetic amyloids were prepared 
through an in vitro fibrillization process starting from recombinant tau K18 protein (Supplementary 
Fig. S1 a-d). The purity of the protein was checked by SDS-PAGE (Supplementary Fig. S1a). The 
resulting amyloids were structurally characterized by atomic force microscopy (AFM) before and 
after a round of 5 minutes of sonication (Supplementary Fig. S2 a-c). As visible from AFM 
images, the sonication process both broke the amyloids into more homogeneous smaller species, 
and disrupts the big aggregates formed as a consequence of the deposition of the sticky fibers in 
the wells. Short amyloid aggregates were indeed shown to be internalized more easily by 
cultured cells (Aulic et al. 2014). AFM data were then complemented by TEM analysis 
(Supplementary Fig. S2 d-e). Therefore, in all following experiments we used exclusively the 
sonicated preparations of tau K18 amyloids. We performed proteolytic digestion followed by 
Western blotting, and found that the sonicated preparation of tau fibrils was partially resistant to 
proteinase K (Supplementary Fig. S1e). We then assessed the cytotoxicity of different 
concentrations of the fibrils preparations on all the mouse N2a cell lines used in this study for up 
to 72 hours (Supplementary Fig. S3). We did not detect any significant toxicity after exposure to 
tau K18 amyloids. To quantify the number of internalized fibrils in N2a cells, we used confocal 
microscopy of Alexa 488-labelled tau K18 amyloids. Fluorescent labelling of tau K18 amyloids, 
followed by incubation in cell culture medium and quenching of non-internalized material with the 
vital dye Trypan Blue (Karpowicz et al. 2017), allows a more precise quantification of the 
amyloids by reducing the background signal associated with the use of antibodies. Uptake 
experiments on wild-type N2a showed that, in our model system and in our experimental 
conditions, tau K18 amyloids are spontaneously endocytosed in a time- and concentration 
dependent manner (Supplementary Fig. S4). Higher concentrations (2 M) required only 24 
hours to be taken up by the cells, while in the case of lower concentrations (0.5 M), 72 hours 
were needed in order to have 100% of cells positive for aggregates. 
To assess the contribution of PrPC to the uptake, we treated N2a and N2a Prnp-/- with 2 M of 
488-tau K18 amyloids fibrils for 24 hours, and measured the number of internalized amyloids. We 
found that wild-type N2a cells took up an average number of 77  41 fibrils per cell compared to 
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internalized tau K18 amyloids between wild-type N2a and N2a Prnp-/- cells exhibited the same 
trend in three experiments performed with different clones of cells and independent preparations 
of 488-tau K18 amyloids. Moreover, we repeated the same experiment varying the concentration 
of tau K18 amyloids and the incubation time, and found very similar results in terms of differential 
internalization, therefore confirming the robustness of our findings (Supplementary Fig. S6).
As cells change their volume during the progression of the cell cycle (Boucrot & Kirchhausen 
2008), we analyzed the cell dimensions in order to rule out the possibility that the higher 
internalization of tau K18 amyloids by N2a cells might be artifactual (Supplementary Fig. S5). 
Indeed, the number of internalized tau K18 amyloids and the cell volume are positively correlated 
(Supplementary Fig. S5a). No difference was found in the cell volumes between N2a and N2a 
Prnp-/- used in the three experiments shown in Fig. 1A and B. (Supplementary Fig. S5b). 
Tau amyloids bind to PrPC and enter cells through an energy-dependent mechanism.
Previous works showed that both A and -synuclein amyloids bind to PrPC in order to exert their 
detrimental effects and, in the case of synuclein, to gain cell entrance (Resenberger et al. 2012; 
Aulic et al. 2017). Therefore, we hypothesized that a similar mechanism might underlie also the 
uptake of tau fibrils. To better define the molecular interaction between the two proteins, we 
performed a pull-down assay in which biotinylated tau amyloids were used as baits to precipitate 
PrPC from N2a cell lysate. The data demonstrate that tau K18 amyloids bind to PrPC in vitro (Fig. 
1C). Evidence of the interaction between the cellular prion protein and monomeric forms of tau is 
already present in literature (Han et al. 2006); however, no previous studies have been 
conducted using fibrillar aggregates of tau. As previous reports claim that PrPC interacts with 
binding partners through its N-terminal tail (Fluharty et al. 2013; Aulic et al. 2017), we tried to 
inhibit the interaction with tau K18 amyloids by pre-incubating N2a cell lysate with POM12 
antibody targeting the N-proximal portion (the octapeptide GQPHGGG/SW of the octarepeat 
region). Lane 5 of Fig. 1D shows that when tau K18 amyloids are incubated with POM12-treated 
N2a lysate and pulled down, no signal is visible after detection with anti-PrP antibody, confirming 
that the interaction has indeed been impaired. 
The binding of the fibrils to PrPC suggests that the internalization might occur through an energy-
dependent, receptor-mediated endocytic pathway rather than via channel diffusion. To test this 
hypothesis, we incubated N2a and N2a Prnp-/- cells with tau fibrils for 6 hours either at 37°C or at 
4°C, which blocks all ATP-dependent processes. As expected, wild-type N2a exhibited a greater 
uptake of tau K18 amyloids under normal culture conditions, with respect to their counterpart not 
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inhibition of the internalization for both cell types, regardless of their genetic background (Fig. 
1F), indicating an ATP-dependent mechanism required for the internalization of tau K18 
amyloids. 
Finally, we validated the contribution of the cellular prion protein to tau K18 amyloids 
internalization by targeting PrPC with monoclonal antibodies directed against the N-proximal 
portion (the aforementioned POM12 antibody), the amino acids 95-100 of the hydrophobic region 
(POM3 antibody) and a conformational epitope spanning amino acids 121-134 and 218-221 of 
the C-terminal domain (POM4 antibody) (Polymenidou et al. 2008). Both POM12 and POM3 
decreased the uptake of tau K18 amyloids to a level similar to that of N2a Prnp-/-cells (Fig. 1G). 
This is in agreement with the findings of a recent study revealing the toxic effects of soluble tau 
aggregates are reverted when at least one of these two PrPC regions are blocked (Ondrejcak et 
al. 2018).  On the contrary, targeting the C-terminal domain of PrPC did not result in any change 
in the amount of internalized tau K18 amyloids (Fig. 1G). 
Figure 1. Uptake of tau K18 amyloids in mouse neuroblastoma cell lines. (A) Confocal 
microscopy images showing the orthogonal views of the central section of the 3D Z-stack for N2a 
and N2a Prnp-/- (in blue) treated with tau K18 fibrils (in green) for 24 hours. (B) Scatter plot 
showing the distribution of the number of internalized fibrils in N2a and N2a Prnp-/- cells. A total of 
three hundred cells were counted in blind in n= 3 experiments with independent cell culture and 
fibrils preparations .  Numbers on top indicate the average number of internalized fibrils. Data 
were evaluated with unpaired T-test with Welch’s correction. Statistical analysis is indicated as: * 
= p <0.05, ** = p< 0.01, *** = p<0.001, **** = p<0.0001.. (C) Western Blot of pulled down samples 
(lanes 1-3) and input samples (lanes 4-6). Lane 1: K18 fibrils only; lane 2: N2a lysate only; lane 3: 
K18 fibrils and cell lysate. Lane 4: K18 fibrils only; lane 5: N2a cell lysate only; lane 6: K18 fibrils 
and cell lysate. The membrane was probed with human anti-PrPC antibody D18 and with anti-
biotin to visualize tau K18 amyloids. n= 3 experiments with independent cell culture and fibrils 
preparations. (D) Western Blot of pulled down samples and input samples. Lane 1: N2a lysate 
only; lane 2: K18 fibrils only; lane 3: K18 fibrils and cell lysate. Lane 4: N2a cell lysate + POM12; 
lane 5: N2a cell lysate + POM12 + tau K18 amyloids. The membrane was probed with human 
anti-PrPC antibody D18 and with anti-biotin to visualize tau K18. (E) and (F) Internalization of tau 
K18 amyloids by N2a and N2a Prnp-/- cells at 37°C (E) and 4°C (F). Images were acquired using 
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one of the central sections of the stack, both as separate channels and as a merge of the two 
channels. n= 3 experiments with independent cell culture and fibrils preparations. (G) Scatter 
plots representing the distribution of internalized fibrils in N2a cells treated only with tau K18 
fibrils and in N2a that were pre-treated with different anti-PrPC antibodies. Numbers on top 
indicate the average number of internalized fibrils. Data were evaluated with unpaired T-test with 
Welch’s correction. Statistical analysis is indicated as: *= p<0.05; **= p<0.01; ***= p<0.001.
Tau fibrils induce an increase of the endogenous prion protein that localizes on the cell 
membrane. 
To better characterize the mutual relationship between tau amyloids and PrPC, we asked if the 
treatment with tau K18 fibrils has any effect on the endogenous levels of PrPC at different 
timepoints (Fig. 2, A-B). After 72 hours of incubation, we found an increase of around 60% of the 
total PrPC level in N2a cells, while at 24 and 48 hours no changes were detected. This effect was 
dependent on the presence of the aggregates in the culture medium, because when treated cells 
are passaged and kept in fibrils-free medium, PrPC level went back to basal levels (Fig. 2A). The 
observed variation in total PrPC occurs only at the protein level, since we did not find any increase 
in the levels of Prnp mRNA after tau K18 amyloids treatment (Supplementary Fig. S7). 
Immunofluorescence stainings of PrPC in untreated and tau-treated N2a cells revealed that 
around 35% of the excess PrPC was localized on the plasma membrane (Fig.3). The increase in 
PrP-associated fluorescence levels occured only after 72 hours of incubation with tau amyloids, 
in agreement with Western Blot data (Fig. 3). N2a cells treated with 10 µM chlorpromazine, which 
is known to decrease the amount of PrPC on the surface of the cells (Stincardini et al. 2017), were 
used as control to assess the validity of the experimental method (Supplementary Fig. S8).
Figure 2. Exposure of N2a cells to tau K18 fibrils induces an increase of the endogenous 
prion protein. (A) Western blot analysis of N2a cells treated with 2 µM of tau K18 fibrils for 24, 
48 and 72 hours and of the first passage of N2a treated for 72 hours. Membranes were probed 
with human anti-PrP antibody D18. (B) Quantification of three independent experiments. Data are 
represented as the percentage of total PrP relative to ß-actin. ß-actin is a loading control. Data 
are represented as mean ± SD. Data were evaluated by unpaired T-test. Statistical analysis is 
indicated as: n.s.= not significant; *= p<0.05; **= p<0.01; ***= p<0.001. 
Figure 3. Exposure of N2a cells to tau K18 fibrils induces an increase of the endogenous 
prion protein. (A) Representative immunofluorescence images of untreated and treated N2a at 
three different timepoints. Membrane staining for PrPC was performed at 4°C on alive cells using 
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associated to PrPC between control cells and cells treated for 72 hours. In all the images, the 
green signal corresponds to Tau K18 amyloids and the red signal to PrPC. (B) Scatter plot of the 
intensity of the PrP-associated membrane staining of treated N2a compared to control cells. The 
intensity values, which correlates with the levels of PrP on the membrane, is reported as the ratio 
between the average intensities of treated and control cells for each timepoint. Controls have 
been normalized to 1. The three values represent three independent experiments, in which 700 
cells for each condition were analysed. Data have been evaluated with unpaired T-test. Statistical 
analysis is indicated as: n.s.= not significant; *= p<0.05; **= p<0.01; ***= p<0.001. (C) Orthogonal 
views of the central section of the 3D Z-stack for N2a control cells and N2a treated with K18 
amyloids for 72 hours. 
Tau amyloids lower PrPSc levels in cell lines infected with different prion strains
Although the process of prion conversion and PrPSc formation depends mainly on the presence of 
PrPC, recent studies revealed that it can be affected by the concomitant presence of intracellular 
amyloids of other neurodegeneration-related proteins (Aulic et al. 2017). In the case of tau 
protein, this assumes clinical relevance as some cases were documented where prion pathology 
co-exists with tau deposits (Rossi et al. 2019; Piccardo et al. 2017; Ghetti et al. 1996). To assess 
the effect of tau fibrils on PrPSc levels, we exposed a neuroblastoma cell line persistently infected 
with RML prion strain (ScN2a RML) to two different concentrations of tau K18 amyloids and we 
analysed the PK-resistant PrPSc at different timepoints (Fig. 4A). The quantification of three 
independent experiments (Fig. 4B), showed that the time required for PrPSc clearance is 
dependent on the concentration of tau K18 amyloids. Indeed, cells treated with 5 µM tau K18 
amyloids showed significantly less prions after 48 hours, while treating with a lower concentration 
of tau K18 amyloids (2 µM) required 72 hours to lead to a 50% decrease in prion burden. 
Although the highest concentration of tau K18 amyloid proved to be more effective in clearing 
PrPSc after 72 hours, we chose to use 2 µM for further experiments, as it gave more reproducible 
results. Immunofluorescence data (Fig. 4C) revealed that tau K18 amyloids are taken up by 
ScN2a cells, and they appear to co-localize with lysosomes (Supplementary Fig. S9).  Next, we 
wondered if PrPSc levels could remain low upon passaging, even in the absence of tau fibrils. 
After a 72 hours-incubation with 2 µM of tau K18 amyloids, cells were kept in culture for 5 
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amyloids and remained low through two subsequent passages (Fig. 5A and B), while monomeric 
K18 used as a control did not affect prion levels.  However, although the reduction observed after 
the initial passages was quite pronounced, it was not maintained after the third passage without 
fibrils, where PrPSc levels rose again to their initial level (Fig. 4C). A longer incubation with the 
fibrils did not result in a complete clearance of PrPSc, since a weak signal was still present at 
passage 3 (Supplementary Fig. S10). 
We tested the strain dependency of tau K18-induced clearance of PrPSc by repeating the 
treatment on ScN2a infected with the 22L prion strain (Figure 4C). Also in this case we reported a 
strong reduction in the PrPSc load after the administration of the fibrils, indicating that the 
mechanism activated by tau K18 is not affected by strain differences.
Taken together, these results show that tau K18 amyloids are able to clear PrPSc in cultured cells 
permanently replicating different prion strains, and that they have to be present in the cell culture 
medium in order to keep the prion burden low.  This effect occurs probably through a direct 
interaction with either PrPC or PrPSc. Since tau K18 amyloids interact with PrPC, we hypothesized 
that the fibrils might bind and reduce the availability of PrPC for PrPSc-induced conversion. Indeed, 
we found that the treatment with K18 fibrils promotes the -cleavage of PrPC with the formation of 
the N1 and C1 fragment, thus reducing the pool of PrPC needed for the conversion (Fig. 5E). 
Figure 4. Tau-induced PrPSc clearance in ScN2a RML cell line at different timepoints. (A) 
Western Blot analysis of PK-resistant PrPSc upon treatment with different concentrations of tau 
K18 amyloids at 24 hours, 48 hours and 72 hours. (B) Quantification of three independent 
experiments. Values are shown as a percentage of PK-resistant form relative to β-actin. β-Actin is 
a loading control. Data are represented as mean ± SD. Data were evaluated by one-way ANOVA 
with multiple comparisons. Statistical analysis is indicated as: *= p < 0.05, **= p < 0.01, ***= p < 
0.001. (C) Confocal microscopy image showing the orthogonal views of the central section of the 
3D Z-stack of ScN2a RML cells treated with 2 µM of tau K18 amyloids (in green) for 72 hours. 
Figure 5. Clearance of PrPSc from prion-infected ScN2a cell lines after treatment with tau 
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treatment with tau K18 amyloids for 3 days from the addition of the fibrils (passage 0) to passage 
2. (B) Quantification of n=3 experiments with independent cell culture and fibrils preparations. 
Values are shown as a percentage of PK-resistant form relative to β-actin. β-Actin is a loading 
control. Data are represented as mean ± SD. Data were evaluated by one-way ANOVA with 
multiple comparisons. Statistical analysis is indicated as: *= p < 0.05, **= p < 0.01, ***= p < 0.001. 
(C) Western Blot analysis of further passaging of treated cells shown in (A), from passage 3 to 
passage 5. (D) Western blot analysis of PK-resistant PrPSc in ScN2a 22L cell lysates upon 
treatment with tau K18 amyloids for 3 days. (E) Electrophoretic pattern of PNGase F digested 
PrP in ScN2a control cells and cells treated with tau K18 fibrils. Solid black arrow shows the 
presence of C1 fragment recognized with C-terminal Ab (W226), while the broken black arrow 
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Discussion
A number of reports claim that the role of the cellular prion protein in neurodegeneration is not 
limited to prion disorders, but extends also to the pathogenesis of Alzheimer’s disease and 
synucleinopathies (Resenberger et al. 2011; Resenberger et al. 2012; Aulic et al. 2017; Urrea et 
al. 2017; Ondrejcak et al. 2018). Indeed, several reports indicate that PrPC mediates the 
neurotoxicity of several protein aggregates (-synuclein, amyloid ) in two different ways. Firstly, 
PrPC was reported to act as a membrane receptor to facilitate their internalization(Ondrejcak et al. 
2018; Chen et al. 2010; De Cecco & Legname 2018; Aulic et al. 2017). Secondly, PrPC may 
function as a transducer of their detrimental effects through the activation of metabotropic 
glutamate receptors (Um et al. 2012; Abe & Bonini 2013). 
Our study gives a more detailed insight into the molecular mechanisms of the interplay between 
tau and the prion protein, and points towards an alternative and complementary role of PrPC in 
the pathogenic process of tauopathies. Indeed, as the involvement of PrPC in the tau-induced 
toxicity and impairment of long-term potentiation seems to be assessed (Ondrejcak et al. 2018; 
Ondrejcak et al. 2019), we demonstrated that the interaction between the two proteins is deeper 
than expected, and extends also to the cell-to cell propagation of tau pathology.  
First, we showed that sonicated tau K18 fibrils bind to PrPC. The existence of an interaction 
between the two partners is the first mandatory step in the cascade of events leading to PrPC-
dependent internalization. Although there is proof of the interaction of the prion protein with 
monomeric full-length tau in the literature (Han et al. 2006), no experiments had been performed 
so far using synthetic aggregates. In addition, the existence of a direct interaction between PrPC 
and amyloid species is still an open question. Recently, La Vitola et al. (La Vitola et al. 2019) 
could not detect any binding between PrPC and α-synuclein amyloids in hippocampal neurons 
and in mouse models. These results are in contrast with a full body of evidence pointing at this 
interaction as the first step in a cascade of events leading to amyloid-induced neurotoxicity and 
cellular internalization of α-synuclein aggregates (Aulic et al. 2017; Ferreira et al. 2017). 
Regarding tau, what we observed is in line with the findings of Ondrejcak et al. (Ondrejcak et al. 
2018; Ondrejcak et al. 2019), as in both cases the direct targeting of PrPC with antibodies 
reduced the internalization of tau amyloids and their effects on long-term potentiation, 
respectively. The negative results obtained by La Vitola might be due to the highly variable 
conformation of α-synuclein oligomers and to the fact that only one type of preparation was 
tested, as stated by the authors themselves. Moreover, oligomers are likely to be transient 
species in the process of aggregation, and as such to have a more heterogenous conformation. 
Since PrPC appears to bind to -sheet enriched regions, the different structural organization of 
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tau fibrils throughout all this work. The amyloid-like nature of our synthetic tau K18 amyloid was 
further assessed by digestion with 10 µg/mL proteinase K, which resulted in a pattern of bands 
with lower molecular weight compared to the undigested sample. The relative resistance of 
protein aggregates to proteinase K digestion is another known feature of amyloids, and it appears 
to be correlated to the structural organization of the conformer and to the amount of -sheet 
elements. The results we obtained are in line with previous works showing that recombinant tau 
aggregates are resistant to protease degradation (Iba et al. 2013; Falcon et al. 2015; Meyer et al. 
2016), and therefore we concluded that our synthetic tau K18 fibrils can be considered as bona-
fide amyloids.
Although recent work (Ghag et al. 2018) points at the sonicated synthetic aggregates as the 
species responsible for toxicity, we did not detect any significant effect after exposure to tau K18 
amyloids. This discrepancy might be due to small differences in the preparations of the amyloids 
(isoform of tau, amount of heparin, shaking protocol, sonication procedure). For example, our 
sonicated fibrils are slightly smaller than the ones used in Ghag et al. (average height 4-6 nm), as 
they include also fragments with height ranging from 2 to 4 nm. As sonication randomly breaks 
long fibrils into smaller fragments, it might generate large variability between different 
preparations, and sometimes also among batches prepared in the same way. Indeed, as it can 
be observed from the graphs in Supplementary Fig. 3, we could detect mild cytotoxicity in all cell 
types with some batches of fibrils, even if it was not statistically significant. From the trend of the 
data, the slight reduction in cell viability appears to be correlated with the concentration of tau 
amyloids that was used. N2a Prnp-/- showed the strongest effect in terms of reduction of cell 
viability, and we think that this might be related to the increased sensitivity of cells lacking PrPC to 
a wide range of insults (Brown et al. 1997; Brown et al. 2002).
We found that cells that express PrPC on the cell surface (N2a) internalize more tau amyloids 
compared to the same cells from which the gene encoding PrPC was removed (N2a Prnp-/-). N2a 
Prnp-/- cells, even if deprived of PrPC, were able to internalize a discrete number of fibrils, 
consistently with previous reports of multiple mechanisms occurring at the same time and 
independently from each other. However, when the prion protein was present, the number of 
internalized fibrils almost doubled, meaning that the PrPC-mediated pathway contributed strongly 
to this process. 
We performed a meta-analysis on published genomic and proteomic data to confirm the validity 
of our model and to exclude that the knock-down of PrPC might in some way interfere with the 
expression of other tau receptors (Morozova et al. 2019; Rauch et al. 2018). Concerning N2a cell 
line, we found that specific tau receptors are poorly expressed. Indeed, expression of both 
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LRP1 has been reported (source: BioGPS Mouse Cell Type and Tissue Gene Expression 
Profiles). Nevertheless, as previously mentioned, tau amyloids have been shown to enter cells 
also through macropinocytosis and tunneling nanotubes, which might explain the results obtained 
in N2a Prnp-/-. Concerning PrP knock-out cell lines, a proteomic study conducted in NMuMG cells 
(Mehrabian et al. 2014) only revealed the mild dysregulation of the HSPG syndecan-1 in knock-
out cells compared the wild-type counterpart. However, this protein is typically expressed in 
epithelial and endothelial cells, therefore we deem it unlikely that it might play a relevant role in 
our neuroblastoma cell model. More recently, Macedo et al. conducted a proteomic study on wild-
type and Prnp-/- PK1 neuroblastoma cell line to identify all differentially expressed proteins, with a 
specific focus on membrane proteins (Macedo et al. 2017). The analysis resulted in six 
differentially expressed proteins, none of which has ever been associated to the process of tau 
internalization. Hence, we could conclude that there is no evidence pointing towards an effect of 
Prnp ablation on the expression of other tau receptors.
The PrPC-mediated internalization of tau k18 amyloids occurs most likely via endocytosis, since 
we observed an inhibition of the uptake upon lowering the temperature to 4°C. A similar effect 
occurred also with -synuclein, suggesting that common energy-dependent mechanisms regulate 
the receptor-mediated internalization of different aggregated proteins (Reyes et al. 2019; Bieri et 
al. 2018; Desplats et al. 2009; Lee et al. 2008).  The specific pathways regulating A amyloids 
internalization are under debate, as endocytosis and passive diffusion were proposed to co-occur 
in the same neuron (Kandimalla et al. 2009). Nevertheless, the majority of data indicate a 
dynamin-dependent pathway, rather than clathrin-dependent, as the principal mechanism driving 
the internalization of -synuclein and A amyloids. Concerning tau, clathrin-mediated processes 
have been excluded in many different cell models, while the exact role of dynamin-dependent 
endocytosis is still unclear (Holmes et al. 2013; Demaegd et al. 2018; Evans et al. 2018). 
Although in one case the inhibition of dynamin did not result in decreased uptake (Holmes et al. 
2013), other works showed that treatments with the drug Dynasore reduced the internalization of 
tau aggregates. Moreover, the inhibition of Bin1 protein, which interacts with clathrin and recruits 
dynamin in a mixed pathway, led to an impairment of the entrance of tau aggregates composed 
only of the microtubule-binding domains (Calafate et al. 2016). Therefore, we speculate that 
dynamin might be involved in the energy-dependent mechanism of PrPC-mediated uptake in our 
cell model. 
The role of PrPC was orthogonally confirmed by the observation that the targeting of the N-
terminus or the hydrophobic domain of PrPC using antibodies lead to a reduction of the 
internalized fibrils. Most intriguingly, we discovered that the interaction between PrPC and tau 
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tau aggregates leads to an increase of the cellular level of the prion protein, which is re-localized 
mainly on the plasma membrane where it could perform its receptor activity. The increase in PrPC 
could be due either to the trafficking of the newly synthesized PrPC on the surface, or to a longer 
retention on the membrane as a consequence of the interaction with the fibrils, as no changes in 
Prnp expression levels were detected.  Given that the prion protein facilitates the internalization 
of tau amyloids, we hypothesize that a higher amount of PrPC exposed outside the cells might 
result in more extracellular tau fibrils gaining cell entrance Although this phenomenon might be a 
simple side-effect of the interaction and subsequent internalization of the aggregates, we deem it 
likely that tau fibrils are boosting their own spreading by increasing the number of receptor 
molecules on the cell surface. A similar hypothesis has been proved true in the case of 
intercellular transfer of tau amyloids through tunneling nanotubes, where extracellular tau species 
(monomers and fibrils) activated the formation of new nanotubes and therefore facilitated fibrillar 
tau transport between neurons (Tardivel et al. 2016). On the other hand, protein aggregates (tau 
and synuclein) are trafficked in early endosomes and lysosomes after the internalization (Evans 
et al. 2018; Masaracchia et al. 2018; Aulic et al. 2017). The need of the cell to deal quickly with a 
large amount of exogenous and potentially dangerous material might clog the degradation 
system, with subsequent impact on the normal turnover of the endogenous proteins. Indeed, a 
similar effect on PrP levels has been reported after treatment with synuclein fibrils (Aulic et al. 
2017), although the localization of the excess protein was not investigated. Alternatively, the 
binding of the amyloids to PrPC on the cell membrane might simply impede its internalization and 
retain the protein in its position, therefore leading to a general increase as the newly synthesized 
protein follows its normal pathway all the way up to the surface.
Together with the previously mentioned electrophysiological data (Ondrejcak et al. 2018; 
Ondrejcak et al. 2019), our observations on the mechanicistic role of PrPC in the spreading of tau 
pathology provide a more comprehensive outlook on the progression of tauopathies. Moreover, 
this work gives additional strong and orthogonal evidence to the therapeutic potential of anti-PrP 
antibodies in the treatment of tauopathies.  
We observed that the scrapie load in cell cultures decreased after incubation with tau K18 fibrils. 
Tau-mediated clearance was independent of the PrPSc conformation, as a similar reduction was 
observed for both RML and 22L prion strains. One way in which tau K18 amyloids might lead to 
PrPSc reduction is through a direct binding to either PrPC or PrPSc, inhibiting prion conversion by 
depleting respectively the pool of the substrate or of the template. Indeed, tau K18 fibrils bind to 
PrPC and promote its processing into the N1 and C1 fragments, which reduces the amount of 
cellular prion protein available for the conversion. The similar effects observed after the exposure 
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target. As the exact structure of PrPSc is undefined, the structural differences distinguishing the 
RML and 22L prion strains are not known, and could be so subtle not to impact the binding of 
K18 fibrils in a detectable manner. In view of the wealth of data suggesting that PrPC interacts 
with many amyloids, the most parsimonious interpretation is that tau K18 amyloids interacts with 
the PrPC. 
Our findings are likely to have a deep impact on the explanation of the co-presence of tau and 
PrP deposits found in some cases of prion diseases. Specifically, in some patients the prion 
protein burden was found to be correlated with the presence of tau aggregates in the forms of 
rods and stubs (Reiniger et al. 2011), and dystrophic neurites positive for anti-phospho tau 
antibodies were found to colocalize with prion plaques in cases of sCJD, vCJD and GSS 
(Giaccone et al. 2008; Sikorska et al. 2009). While the co-deposition of NFTs and prion plaques 
is considered as a sort of side-effect in classical prion disorders, it becomes the major sign of a 
rare form of prion disorder called PrP-cerebral amyloid angiopathy (PrP-CAA) (Ghetti et al. 1996). 
This peculiar case of dementia arises from a nonsense mutation at codon 145 of PrP, and is 
characterised by extended PrP deposition in the walls of small and medium-size vessels, as well 
as in the surrounding parenchyma. Neurofibrillary tangles and neurophil threads are abundant 
especially in the pyramidal and granule cells of the hippocampus, and are closely associated with 
parenchymal amyloid plaques. However, the relationship between prion and tau pathologies 
remain elusive. In view of our data, we think that the presence of both protein deposits might not 
be a pure coincidence. While it has been proposed that PrP deposits might in some cases trigger 
tau phosphorylation, our observations suggest that also tau amyloids could influence the fate of 
PrP aggregates. As already discussed for the cases of the co-deposition of PrP and synuclein 
(Aulic et al. 2017), we believe that deeper investigations on these cases (i.e. duration of the 
disease course, severity of the symptoms) might open new possible interpretation of this 
phenomenon.
In conclusion, here we provide evidence of another relevant role for PrPC in mediating the 
internalization of exogenous tau fibrils, therefore contributing to the cell-to-cell spreading of tau 
K18 amyloids and to the onset of the pathology. The interaction between tau fibrils and the 
cellular prion protein seems to affect also the process of prion replication in prion-infected cell 
lines. This occurs probably through the inhibition of the mechanism of PrPC conversion into PrPSc, 
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies




HRP conjugated goat anti-mouse antibody Jackson laboratories Cat #115-035-003
RRID:AB_1001528
9
mouse anti-tau RD4 antibody Millipore Cat #05-804
RRID:AB_310014




Human anti-PrP antibody D18 Dr. Stanley Prusiner 
(UCSF)
N/A
Mouse anti-PrP antibody W226
Bacterial and Virus Strains
BL21(DE3) E.coli bacterial strain New England 
Biolabs
Cat #C2527H
Chemicals, kits and other equipment
HiTrap SP FF columns Sigma/Merck Cat #GE17-5054-
01
HiLoad® 26/600 Superdex® 200 pg Sigma/Merck Cat #GE28-9893-
36
AlexaFluor 488 succinimidyl ester ThermoFisher Cat #A20000
HCS Cell Mask Blue Stain ThermoFisher Cat #H32720
Heparin sodium salt Sigma Cat #H3149
3 mm glass beads Sigma Cat #1040150500
LysoTracker Red DND-2 dye ThermoFisher Cat #L7528
Complete™ ULTRA Tablets, EDTA-free, glass 
vials Protease Inhibitor Cocktail
Sigma Cat #5892953001
Pierce BCA Protein Assay kit ThermoFisher Cat #23225
NeutrAvidin Agarose Resins ThermoFisher Cat #29200
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Fluoromount-G ThermoFisher Cat #00-4958-02
Immobilon PVDF membranes Millipore Cat #IPVH00010
PureLink RNA MiniKit with TRIzol® Reagent  ThermoFisher Cat #12183018A
PureLink DNAse Set Thermofisher Cat #12185010
iQ™ SYBR® Green Supermix Bio-Rad Cat #170-8882
PNGaseF New England 
Biolabs
Cat #P0704L
Geneticin (G418) ThermoFisher 
Scientific
Cat #10131035
Opti-MEM reduced serum medium without phenol ThermoFisher 
Scientific
Cat #11058-21
Minimum Essential Medium (MEM) GIBCO Cat #32561029
Penicillin-streptomycin (PenStrep) ThermoFisher 
Scientific
Cat #25300-054
Fetal Bovine Serum (FBS) Cat# SV30160.03HI GE Healthcare 
Bio-Sciences 
Austria GmbH 










Immobilon Classico Western HRP Substrate  Merck #WBLUC0500
Dimethyl sulfoxide (DMSO) Sigma #D8418-50ML
Experimental Models: Cell Lines
Neuro-2a cell line ATCC N/A
Neuro-2a, Prnp-/- Dr. Gerold Schmitt-
Ulms (Mehrabian et 
al., 2014)
N/A
Scrapie Neuro-2a, RML infected Dr. Stanley Prusiner 
(Butler et al., 1988)
N/A
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Forward primer targeting the Prnp transcript for 
qPCR: GAGACCGATGTGAAGATGATGGA 
This paper N/A
Reverse primer targeting the Prnp transcript for 
qPCR: TAATAGGCCTGGGACTCCTTCTG
This paper N/A
GAPDH housekeeping gene forward primer for 
qPCR: CCTGCACCACCAACTGCTTA
This paper N/A





pcDNA3.1-Mouse Prp Full-length Aulic et al., 2014 N/A
Software and Algorithms
Fiji https://fiji.sc N/A

























Figure 1. Uptake of tau K18 amyloids in mouse neuroblastoma cell lines. (A) Confocal microscopy 
images showing the orthogonal views of the central section of the 3D Z-stack for N2a and N2a 
Prnp-/- (in blue) treated with tau K18 fibrils (in green) for 24 hours. (B) Scatter plot showing the 
distribution of the number of internalized fibrils in N2a and N2a Prnp-/- cells. A total of three 
hundred cells were counted in blind in three independent experiments.  Numbers on top indicate 
the average number of internalized fibrils. Data were evaluated with unpaired T-test with Welch’s 
correction. Statistical analysis is indicated as: * = p <0.05, ** = p< 0.01, *** = p<0.001, **** = 
p<0.0001.. (C) Western Blot of pulled down samples (lanes 1-3) and input samples (lanes 4-6). 
Lane 1: K18 fibrils only; lane 2: N2a lysate only; lane 3: K18 fibrils and cell lysate. Lane 4: K18 fibrils 












with human anti-PrPC antibody D18 and with anti-biotin to visualize tau K18 amyloids. (D) Western 
Blot of pulled down samples and input samples. Lane 1: N2a lysate only; lane 2: K18 fibrils only; 
lane 3: K18 fibrils and cell lysate. Lane 4: N2a cell lysate + POM12; lane 5: N2a cell lysate + POM12 
+ tau K18 amyloids. The membrane was probed with human anti-PrPC antibody D18 and with anti-
biotin to visualize tau K18. (E) and (F) Internalization of tau K18 amyloids by N2a and N2a Prnp-/- 
cells at 37°C (E) and 4°C (F). Images were acquired using a confocal microscope as series of Z-
stacks and the analysis was carried out in 3D. Images show one of the central sections of the stack, 
both as separate channels and as a merge of the two channels. (G) Scatter plots representing the 
distribution of internalized fibrils in N2a cells treated only with tau K18 fibrils and in N2a that were 
pre-treated with different anti-PrPC antibodies. Numbers on top indicate the average number of 
internalized fibrils. Data were evaluated with unpaired T-test with Welch’s correction. Statistical 









































Figure 2. Exposure of N2a cells to tau K18 fibrils induces an increase of the endogenous prion 
protein. (A) Western blot analysis of N2a cells treated with 2 µM of tau K18 fibrils for 24, 48 and 
72 hours and of the first passage of N2a treated for 72 hours. Membranes were probed with 
human anti-PrP antibody D18. (B) Quantification of three independent experiments. Data are 
represented as the percentage of total PrP relative to ß-actin. ß-actin is a loading control. Data are 
represented as mean ± SD. Data were evaluated by unpaired T-test. Statistical analysis is indicated 





























































Figure 3. Exposure of N2a cells to tau K18 fibrils induces an increase of the endogenous prion 
protein. (A) Representative immunofluorescence images of untreated and treated N2a at three 
different timepoints. Membrane staining for PrPC was performed at 4°C on alive cells using the 
W226 antibody. The magnified sections show a visible difference in the fluorescence intensity 
associated to PrPC between control cells and cells treated for 72 hours. In all the images, the green 
signal corresponds to Tau K18 amyloids and the red signal to PrPC. (B) Scatter plot of the intensity 
of the PrP-associated membrane staining of treated N2a compared to control cells. The intensity 
values, which correlates with the levels of PrP on the membrane, is reported as the ratio between 
the average intensities of treated and control cells for each timepoint. Controls have been 
normalized to 1. The three values represent three independent experiments, in which 700 cells for 
each condition were analysed. Data have been evaluated with unpaired T-test. Statistical analysis 
is indicated as: n.s.= not significant; *= p<0.05; **= p<0.01; ***= p<0.001. (C) Orthogonal views of 
the central section of the 3D Z-stack for N2a control cells and N2a treated with K18 amyloids for 


















Figure 4. Tau-induced PrPSc clearance in ScN2a RML cell line at different timepoints. (A) Western 
Blot analysis of PK-resistant PrPSc upon treatment with different concentrations of tau K18 
amyloids at 24 hours, 48 hours and 72 hours. (B) Quantification of three independent 
experiments. Values are shown as a percentage of PK-resistant form relative to β-actin. β-Actin is a 
loading control. Data are represented as mean ± SD. Data were evaluated by one-way ANOVA with 
multiple comparisons. Statistical analysis is indicated as: *= p < 0.05, **= p < 0.01, ***= p < 0.001. 
(C) Confocal microscopy image showing the orthogonal views of the central section of the 3D Z-
























Figure 5. Clearance of PrPSc from prion-infected ScN2a cell lines after treatment with tau K18 
amyloids. (A) Western blot analysis of PK-resistant PrPSc in ScN2a RML cell lysates upon treatment 
with tau K18 amyloids for 3 days from the addition of the fibrils (passage 0) to passage 2. (B) 
Quantification of three independent experiments. Values are shown as a percentage of PK-
resistant form relative to β-actin. β-Actin is a loading control. Data are represented as mean ± SD. 
Data were evaluated by one-way ANOVA with multiple comparisons. Statistical analysis is 
indicated as: *= p < 0.05, **= p < 0.01, ***= p < 0.001. (C) Western Blot analysis of further 
passaging of treated cells shown in (A), from passage 3 to passage 5. (D) Western blot analysis of 
PK-resistant PrPSc in ScN2a 22L cell lysates upon treatment with tau K18 amyloids for 3 days. (E) 
Electrophoretic pattern of PNGase F digested PrP in ScN2a control cells and cells treated with tau 
K18 fibrils. Solid black arrow shows the presence of C1 fragment recognized with C-terminal Ab 
(W226), while the broken black arrow indicates the absence of the bands when the membrane 
was probed with N-terminal antibody (SAF34).  
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